Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial
一项 I 期试验分析了 EGFR T790M 阳性非小细胞肺癌患者对第三代 EGFR 酪氨酸激酶抑制剂阿比维替尼的耐药机制
期刊:EBioMedicine
影响因子:10.8
doi:10.1016/j.ebiom.2019.04.030
Zhang, Yi-Chen; Chen, Zhi-Hong; Zhang, Xu-Chao; Xu, Chong-Rui; Yan, Hong-Hong; Xie, Zhi; Chuai, Shao-Kun; Ye, Jun-Yi; Han-Zhang, Han; Zhang, Zhou; Bai, Xiao-Yan; Su, Jian; Gan, Bin; Yang, Jin-Ji; Li, Wen-Feng; Tang, Wei; Luo, Feng Roger; Xu, Xiao; Wu, Yi-Long; Zhou, Qing
